MPM Bioimpact LLC Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

MPM Bioimpact LLC acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 23,000 shares of the biotechnology company's stock, valued at approximately $8,115,000. MPM Bioimpact LLC owned about 0.05% of United Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the business. Man Group plc grew its position in shares of United Therapeutics by 0.7% during the 4th quarter. Man Group plc now owns 46,723 shares of the biotechnology company's stock valued at $16,486,000 after buying an additional 302 shares during the last quarter. Nissay Asset Management Corp Japan ADV grew its position in shares of United Therapeutics by 1.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 5,192 shares of the biotechnology company's stock valued at $1,869,000 after buying an additional 61 shares during the last quarter. Nomura Holdings Inc. bought a new stake in shares of United Therapeutics during the 4th quarter valued at about $2,090,000. Mubadala Investment Co PJSC bought a new stake in shares of United Therapeutics during the 4th quarter valued at about $2,386,000. Finally, NDVR Inc. grew its position in shares of United Therapeutics by 11.4% during the 4th quarter. NDVR Inc. now owns 644 shares of the biotechnology company's stock valued at $227,000 after buying an additional 66 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

Insider Activity

In other news, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $300.93, for a total value of $3,310,230.00. Following the transaction, the executive vice president now directly owns 36,781 shares of the company's stock, valued at approximately $11,068,506.33. This represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the transaction, the director now directly owns 8,480 shares in the company, valued at $2,703,424. This trade represents a 22.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 65,500 shares of company stock worth $20,765,280. Insiders own 10.30% of the company's stock.

United Therapeutics Stock Up 0.5%

UTHR traded up $1.43 during trading on Friday, reaching $305.35. The stock had a trading volume of 518,041 shares, compared to its average volume of 442,569. United Therapeutics Co. has a 1-year low of $264.33 and a 1-year high of $417.82. The stock has a 50 day moving average of $299.95 and a two-hundred day moving average of $340.58. The firm has a market capitalization of $13.77 billion, a price-to-earnings ratio of 13.41, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same quarter in the prior year, the firm earned $6.17 EPS. The company's quarterly revenue was up 17.2% compared to the same quarter last year. On average, research analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on UTHR. HC Wainwright restated a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Monday, May 5th. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective for the company in a research report on Monday, April 21st. Finally, JPMorgan Chase & Co. reduced their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $392.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.